Journal Mobile Options
Table of Contents
Vol. 185, No. 1-3, 2007
Issue release date: June 2007

Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis

Bagnato A. · Rosanò L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


In ovarian carcinoma, acquisition of invasiveness is accompanied by the loss of the epithelial features and the gain of a mesenchymal phenotype, a process known as epithelial-mesenchymal transition (EMT). The endothelin A receptor (ETAR)/endothelin-1 (ET-1) axis is overexpressed in primary and metastatic ovarian carcinoma. In this tumor type, the ET-1/ETAR axis has a critical role in ovarian carcinoma progression by inducing proliferation, survival, neoangiogenesis, loss of intercellular communication and invasion. Recently, we demonstrated that the ET-1/ETAR autocrine pathway drives EMT in ovarian tumor cells by inducing an invasive phenotype through downregulation of E-cadherin, increased levels of β-catenin, Snail and other mesenchymal markers, and suppression of E-cadherin promoter activity. Activation of ETAR by ET-1 triggers a phosphatidylinositol 3-kinase-dependent integrin-linked kinase (ILK)-mediated signaling pathway leading to glycogen synthase kinase-3β (GSK-3β) inhibition, Snail and β-catenin stabilization andtranscriptional programs that control EMT. Transfection of dominant negative ILK or exposure to an ILK inhibitor suppresses the ET-1-induced phosphorylation of GSK-3β as well as Snail and β-catenin protein stability, transcriptional activity and invasiveness, indicating that ET-1/ETAR-induced EMT depends on ILK activity. ETAR blockade by specific antagonists, or reduction by ETAR RNA interference, reverses EMT and cell invasion by inhibiting autocrine signaling pathways. In ovarian carcinoma xenografts, the specific ETAR antagonist ABT-627 suppresses EMT determinants and tumor growth. In human ovarian cancers, ETAR expression is associated with E-cadherin downregulation, N-cadherin expression and tumor grade. In conclusion, our findings demonstrate that ETAR activation by ET-1 is a key mechanism of the complex signaling network that promotes EMT as well as ovarian cancer cell invasion. The small molecule ETAR antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and β-catenin signaling cascade via ETAR blockade may be advantageous in the treatment of ovarian cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Agarwal, R., S.B. Kaye (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Na Rev Cancer 3: 502–516.
  2. Ahmed, N., S. Maines-Bandiera, M.A. Quinn, W.G. Unger, S. Dedhar, N. Auersperg (2006) Molecular pathways regulating epidermal growth factor-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: C1532–C1542.
  3. Auersperg, N., J. Pan, B.D. Grove, T. Peterson, J. Fisher, S. Maines-Bandiera, A. Somassiri, D. Roskelley (1999) E-cadherin induces mesenchymal to epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96: 6249–6254.
  4. Bachelder, R.E., S.O. Yoon, C. Franci, A. Garcia de Herreros, A.M. Mercurio (2005) Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 1681: 29–33.
  5. Bagnato, A., R. Tecce, V. Di Castro, K.J. Catt (1997) Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res 57: 1306–1311.
  6. Bagnato, A., K.J. Catt (1998) Endothelin as autocrine regulators of tumor cell growth. Trends Endocrinol Metabol 9: 378–383.
  7. Bagnato, A., D. Salani, V. Di Castro, J.R. Wu-Wong, R. Tecce, M.R. Nicotra, A. Venuti, P.G. Natali (1999) Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720–727.
  8. Bagnato, A., L. Rosanò, V. Di Castro, A. Albini, D. Salani, M. Varmi, M.R. Nicotra, P.G. Natali (2001) Endothelin receptor blockade inhibits proliferation of Kaposi’s sarcoma cells. Am J Pathol 158: 841–847.
  9. Bagnato, A., A. Cirilli, D. Salani, P. Simeone, A. Muller, M.R. Nicotra, P.G. Natali, A. Venuti (2002) Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 62: 6381–6384.
  10. Bagnato, A., F. Spinella (2002) Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metabol 14: 44–50.
  11. Bagnato, A., L. Rosanò, F. Spinella, V. Di Castro, R. Tecce, P.G. Natali (2003) Endothelin B receptor blockade inhibits dynamic of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436– 1443.

    External Resources

  12. Bagnato, A., P.G. Natali (2004) Endothelin receptors as novel targets in tumor therapy. J Transl Med 2: 16–35.
  13. Barberà, M.J., I. Puig, D. Domingue, S. Julien-Grille, S. Guaita-Esteruelas, S. Peiró, J. Baulida, C. Francí, S. Dedhar, L. Larue, A. García de Herreros (2004) Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 23: 7345–7354.
  14. Batlle, E., E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, A. Garcia De Herreros (2000) The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84–89.
  15. Battistini, B., P. Chailler, P. D’Orleans-Juste, N. Briere, P. Sirois (1993) Growth regulatory properties of endothelins. Peptides 14: 385–399.
  16. Bissell, M.J., D. Radisky (2001) Putting tumours in the context. Nat Rev Cancer 1: 46–54.
  17. Blanco, M.J., G. Moreno-Bueno, D. Sarrio, A. Locascio, A. Cano, J. Palacios, M.A. Nieto (2002) Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21: 3241–3246.
  18. Cano, A., M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, M.A. Nieto (2000) The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83.
  19. Carducci, M.A., J.B. Nelson, M.K. Bowling, T. Rogers, M.A. Eisenberger, V. Sinibaldi, R. Donehower, T.L. Leahy, R.A. Carr, J.D. Isaacson, T.J. Janus, A. Andre, B.S. Hosmane, R.J. Padley (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171–2218.
  20. Carmeliet, P., R.K. Jain (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–257.
  21. Cavallaro, U., G. Christofori (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118–132.
  22. Cruz, A., C. Parnot, D. Ribatti, P. Corvol, J.M. Gasc (2001) Endothelin-1, a regulator of angiogenesis in the chick chrioallantoic membrane. J Vasc Res 38: 536–545.
  23. Dannenberg, A.J., K. Subbaramaiah (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431–436.
  24. Del Bufalo, D., V. Di Castro, A. Biroccio, M. Varmi, D. Salani, L. Rosanò, D. Trisciuoglio, S. Spinella, A. Bagnato (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61: 524–532.
  25. Delcommenne, M., C. Tan, V. Gray, L. Rue, J. Woodgett, S. Dedhar (1998) Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95: 11211–11216.
  26. Denkert, C., M. Kobel, S. Pest, I. Koch, S. Berger, M. Schwabe, A. Siegert, A. Reles, B. Klosterhalfen, S. Hauptmann (2002) Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893–903.
  27. Domìnguez, D., B. Montserrat-Sentis, A. Virgos-Soler, S. Guaita, J. Grueso, M. Porta, I. Puig, J. Baulida, C. Francí, A. García de Herreros (2003) Phosphorylation regulates the subcellular location and activity of the Snail transcriptional repressor. Mol Cell Biol 23: 5078–5089.
  28. Donninger, H., T. Bonome, M. Radonovich, C.A. Pise-Masison, J. Brady, J.H. Shih, J.C. Barrett, M.J. Birrer (2004) Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065–8077.
  29. Faleiro-Rodrigues, C., I. Macedo-Pinto, D. Pereira, V.M. Ferreira, C.S. Lopes (2004) Association of E-cadherin and β-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 35: 663–669.
  30. Ferrandina, G., L. Lauriola, G.F. Zannoni, A. Fagotti, F. Fanfani, F. Legge, N. Maggiano, M. Gessi, S. Mancuso, F.O. Ranelletti, G. Scambia (2002) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13: 1205–1211.
  31. Folberg, R., M.J.C. Hendrix, A.J. Mariotis (2000) Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156: 361–381.
  32. Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, G.L. Semenza (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613.
  33. Guaita, S., I. Puig, C. Francí, M. Garrido, D. Domínguez, E. Batlle, E. Sancho, S. Dedhar, A. García de Herreros, J. Baulida (2002) Snail induction of epithelial-to-mesenchymal transition in tumor cells is accompanied by MUC-1 repression and ZEB1 expression. J Biol Chem 277: 30209–30216.

    External Resources

  34. Guise, T.A., J.J. Yin, K.S. Mohammad (2003) Role of endothelin in osteoblastic bone metastases. Cancer 97: 779–784.
  35. Gupta, R.A., L.V. Tejada, B.J. Tong, S.K. Das, J.D. Morrow, S.K. Dey, R.N. DuBois (2003) Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906–911.
  36. Hannigan, G., A.A. Troussard, S. Dedhar (2005) Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5: 51–63.
  37. Imai, T., A. Horiuchi, T. Shiozawa, R. Osada, N. Kikuchi, S. Ohira, K. Oka, I. Konishi (2004) Elevated expression of E-cadherin and α-, β-, and γ-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35: 1469–1476.
  38. Masaki, T. (2004) Historical review: endothelin. Trends Pharmacol Sci 25: 219–224.
  39. Morris, C.D., A. Rose, J. Curwen, A.M. Hughes, D.J. Wilson, D.J. Webb (2005) Specific inhibition of the endothelin A receptor with ZD4054: clinical and preclinical evidence. Br J Cancer 92: 2148–2152.
  40. Naora, H., D.J. Montell (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355–366.
  41. Nelson, J.B., S.P. Hedican, D.J. George, A.H. Reddi, S. Piantadosi, M.A. Eisenberger, J.W. Simons (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944–949.
  42. Nelson, J.B., K. Chan-Tack, S.P. Hedican, S.R. Magnuson, T.J. Opgenorth, G.S. Bova, J.W. Simons (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663–668.
  43. Nelson, J.B., W.H. Lee, S.H. Nguyen, D.F. Jarrard, J.D. Brooks, S.R. Magnuson, T.J. Opgenorth, W.G. Nelson, G.S. Bova (1997) Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 35–37.
  44. Nelson, J.B., A. Bagnato, B. Battistini, P. Nisen (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110–116.
  45. Nelson, W.J., R. Nusse (2004) Convergence of Wnt, β-catenin, and cadherin pathways. Science 303: 1483–1487.
  46. Oloumi, A., T. McPhee, S. Dedhar (2004) Regulation of E-cadherin expression and β-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 1691: 1–15.
  47. Remuzzi, G., N. Perico, A. Benigni (2002) New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 1: 986–1000.
  48. Rosanò, L., M. Varmi, D. Salani, V. Di Castro, F. Spinella, P.G. Natali, A. Bagnato (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 8340–8346.
  49. Rosanò, L., F. Spinella, D. Salani, V. Di Castro, A. Venut, M.R. Nicotra, P.G. Natali, A. Bagnato (2003a) Therapeutic targeting of endothelin A receptor in human ovarian carcinoma. Cancer Res 63: 2447–2453.
  50. Rosanò, L., F. Spinella, V. Di Castro, M.R. Nicotra, A. Albini, P.G. Natali, A. Bagnato (2003b) Endothelin receptor blockade inhibits molecular effectors of tumor invasion in Kaposi’s sarcoma. Am J Pathol 163: 753–762.
  51. Rosanò, L., F. Spinella, V. Di Castro, M.R. Nicotra, S. Dedhar, A. Garcia de Herreros, P.G. Natali, A. Bagnato (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65: 11649–11657.
  52. Rosanò, L., F. Spinella, V. Di Castro, S. Dedhar, M.R. Nicotra, P.G. Natali, A. Bagnato (2006) Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behaviour in ovarian carcinoma. Mol Cancer Ther 5: 833–842.
  53. Rosivatz, E., I. Becker, K. Specht, E. Fricke, B. Luber, R. Busch, H. Hofler, K.F. Becker (2002) Differential expression of the epithelial-mesenchymal transition regulators Snail, SIP1, and twist in gastric cancer. Am J Pathol 161: 1881–1891.
  54. Roskelley, C.D., M.J. Bissell (2002) The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 12: 97–104.
  55. Salani, D., V. Di Castro, M.R. Nicotra, L. Rosanò, R. Tecce, A. Venuti, P.G. Natali, A. Bagnato (2000a) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 1537–1547.
  56. Salani, D., G. Taraboletti, L. Rosanò, V. Di Castro, P. Borsotti, R. Gavazzi, A. Bagnato (2000b) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157: 1703–1711.
  57. Savagner, P. (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912–923.
  58. Sood, A.K., M.S. Fletcher, J.E. Coffin, M. Yang, E.A. Seftor, L.M. Gruman, D.M. Gershenson, M.J. Hendrix (2004) Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899–909.
  59. Spinella, F., L. Rosanò, V. Di Castro, P.G. Natali, A. Bagnato (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor 1α in ovarian carcinoma cells. J Biol Chem 277: 27850–27855.
  60. Spinella, F., L. Rosanò, V. Di Castro, M.R. Nicotra, P.G. Natali, A. Bagnato (2003) Endothelin-1 decreases gap-junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 278: 41294–41301.
  61. Spinella, F., L. Rosanò, V. Di Castro, P.G. Natali, A. Bagnato (2004a) Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279: 46700–46705.
  62. Spinella, F., L. Rosanò, V. Di Castro, M.R. Nicotra, P.G. Natali, A. Bagnato (2004b) Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin Cancer Res 10: 4670–4679.
  63. Sugimachi, K., S. Tanaka, T. Kameyama, K. Taguchi, S. Aishima, M. Shimada, K. Sugimachi, M. Tsuneyoshi (2003) Transcriptional repressor Snail and progression of human hepatocellular carcinoma. Clin Cancer Res 9: 2657–2664.
  64. Thiery, J.P. (2002) Epithelial-mesenchymal-transitions in tumor progression. Nat Rev Cancer 2: 442–454.
  65. Umhauer, S., R.J. Ruch, J. Fanning (2000) Gap junctional intercellular communication and connexin 43 expression in ovarian carcinoma. Am J Obstet Gynecol 182: 999–1000.
  66. Vacca, F., A. Bagnato, K.J. Catt, R. Tecce (2000) Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60: 5310–5317.
  67. Venuti, A., D. Salani, V. Manni, F. Poggiali, A. Bagnato (2000) Expression of endothelin-1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 14: 2277–2283.
  68. Wong, A.S., S.L. Maines-Bandiera, B. Rosen, M.J. Wheelock, K.R. Johnson, P.C. Leung, C.D. Roskelley, N. Auersperg (1999) Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer 81: 180–188.
  69. Wulfing, P., R. Diallo, C. Kersting, C. Wulfing, C. Poremba, A. Rody, R.R. Greb, W. Bocker, L. Kiesel (2003) Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9: 4125–4131.
  70. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, T. Masaki (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415.
  71. Yook, J.I., X.Y. Li, I. Ota, E.R. Fearon, S.J. Weiss (2005) Wnt-dependent regulation of the E-cadherin repressor Snail. J Biol Chem 280: 11740–11748.
  72. Zhou, B.P., J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, M.C. Hung (2004) Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6: 931–940.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50